Shorla Oncology, a Clonmel, Ireland- and Cambridge, MA-based pharmaceutical company, raised $35M in Series B funding.
The round was led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland.
The company intends to use the funds to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to market that will address drug shortages, and improving the preparation and application of oncology medication.
Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a pharmaceutical company with an advanced pipeline of oncology drugs for orphan and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage or the drug applications are inadequate for the target population.
Shorla recently announced the FDA approval and market launch of Nelarabine Injection, marking its first approval in the US.
FinSMEs
04/10/2023